|
11.11.2024 14:43:29
|
Why Is RAPT Therapeutics Stock Falling In Pre-market?
(RTTNews) - RAPT Therapeutics, Inc. (RAPT) said it is terminating zelnecirnon program. Zelnecirnon was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and atopic dermatitis, and both trials were placed on clinical hold by the FDA in February 2024. The company subsequently closed both studies. Following feedback recently received from the FDA, the company has stopped zelnecirnon program.
Brian Wong, President and CEO of RAPT, said: "We plan to continue advancing our next generation CCR4 compounds with improved safety margins for inflammatory disease and expect to identify a new candidate in the first half of 2025."
Shares of RAPT Therapeutics are down 49% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
Analysen zu RAPT Therapeutics Inc Registered Shs
Jahresrückblick & Jahresausblick 2024/2025 – Wall Street Live mit Tim Schäfer
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| RAPT Therapeutics Inc Registered Shs | 1.85 | 12.12% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Vorweihnachtliche Zurückhaltung: SMI schlussendlich im Plus -- DAX geht schwächer aus dem HandelDer heimische Aktienmarkt schloss am Montag im Plus, wohingegen sich der deutsche Aktienmarkt abwärts bewegte.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |